Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P960058/S167

HiResolution Bionic Ear System

Advanced Bionics · Decision date Jul 22, 2026

FDA DECISIONP960058/S167

What did the FDA approve?

FDA records P960058/S167 as a supplement to PMA P960058, with the supplement type “Panel Track”. The recorded decision is approval, dated Jul 22, 2026.

FDA approval order statement

Unilateral Hearing Loss The HiResolution Bionic Ear System is indicated for individuals with unilateral hearing loss who meet the following criteria: Asymmetric Hearing Loss (AHL) Individuals with AHL are defined as those with a mild to moderately severe hearing loss in the better ear, i.e., a 4PTA of 31 to 65 dB HL at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz, with a difference of at least 15 dB in the 4PTA between ears. It is recommended that individuals with AHL have at least two (2) weeks experience wearing an appropriately fitted Contralateral Routing of Signal (CROS) system or suitable hearing device prior to cochlear implantation. The ear to be implanted will be as follows: Adults (18 years of age or older): Severe to profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 80 dB HL) A score of = 20% on a Consonant-Nucleus-Consonant (CNC) word test Children (5 years through 17 years of age): Profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 90 dB HL) Insufficient functional access to sound in the ear to be implanted must be determined by aided speech perception test scores of 5% or less on a developmentally appropriate monosyllabic word list when tested in the ear to be implanted alone. Single-Sided Deafness (SSD) Individuals with SSD are defined as those with normal hearing or mild sensorineural hearing loss in the better ear (4PTA of = 30 dB HL at 500, 1000, 2000, and 4000 Hz). It is recommended that individuals with SSD have at least two (2) weeks experience wearing an appropriately fitted Contralateral Routing of Signal (CROS) system or suitable hearing device prior to cochlear implantation. The ear to be implanted will be as follows: Adults (18 years of age or older): Severe to profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 80 dB HL) A score of = 20% on a Consonant-Nucleus-Consonant (CNC) word test Children (5 years through 17 years of age): Profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 90 dB HL) Insufficient functional access to sound in the ear to be implanted must be determined by aided speech perception test scores of 5% or less on a developmentally appropriate monosyllabic word list when tested in the ear to be implanted alone.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Ear, Nose, Throat
Decision date
Jul 22, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P960058/S167
Regulatory pathway
PMA supplement
Product code
MCM
Decision code
APPR
Decision date
Jul 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, cochlear.

Product code
MCM
FDA device class
3

For the original device and its historical approval scope, see PMA P960058. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P960058 · Original PMA

    CLARION MULTI-STRATEGY COCHLEAR IMPLANT

  2. P960058/S167 received

    Application receipt date recorded by FDA.

  3. P960058/S171 · Related supplement

    HiResolution Bionic Ear System

  4. P960058/S172 · Related supplement

    HiResolution Bionic Ear System

  5. P960058/S170 · Related supplement

    HiResolution Bionic Ear System

  6. P960058/S174 · Related supplement

    HiResolution Bionic Ear System Ultra and Ultra 3D Thin PCB

  7. P960058/S173 · Related supplement

    HiResolution Bionic Ear System

  8. P960058/S175 · Related supplement

    HiResolution Bionic Ear System

  9. P960058/S167 · FDA decision

    Panel Track

  10. P960058/S177 · Related supplement

    HiResolution Bionic Ear System

  11. P960058/S178 · Related supplement

    CLARION MULTI-STRATEGY COCHLEAR IMPLANT

Timeline entries are records held by MedtechLedger for P960058. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960058

Product / regulatory recordCompanyPathwayDecision dateSource
Advanced BionicsPMA approvalJun 26, 1997FDA
Advanced BionicsPMA supplementAug 20, 2025FDA
Advanced BionicsPMA supplementOct 14, 2025FDA
Advanced BionicsPMA supplementJan 23, 2026FDA
Advanced BionicsPMA supplementApr 9, 2026FDA
Advanced BionicsPMA supplementApr 16, 2026FDA
Advanced BionicsPMA supplementApr 16, 2026FDA
Advanced BionicsPMA supplementSep 4, 2026FDA
Advanced BionicsPMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code MCM

Product / regulatory recordCompanyPathwayDecision dateSource
Med-El Corp.PMA supplementOct 9, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementApr 30, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Advanced Bionics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
28515 Westinghouse Pl., Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records